Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.61 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1597146 | 0.97 | DPP4 (0.58) | DPP4DPP7DPP8CYP2D6DPP9 | |
| SCHEMBL6820877 | 0.97 | DPP4 (0.58) | DPP4DPP7DPP8CYP2D6DPP9 | |
| SCHEMBL1598401 | 0.85 | DPP4 (0.55) | DPP4DPP7DPP8CYP2D6DPP9 | |
| SCHEMBL1598400 | 0.85 | DPP4 (0.55) | DPP4DPP7DPP8CYP2D6DPP9 | |
| SCHEMBL3934702 | 0.83 | DPP4 (0.48) | DPP4DPP7DPP8CYP2D6DPP9 | |
| SCHEMBL1598039 | 0.82 | DPP4 (0.47) | DPP4DPP7DPP8CYP2D6DPP9 | |
| SCHEMBL1598037 | 0.82 | DPP4 (0.47) | DPP4DPP7DPP8CYP2D6DPP9 | |
| SCHEMBL8695496 | 0.82 | DPP4 (0.47) | DPP4DPP7DPP8CYP2D6DPP9 | |
| SCHEMBL9075518 | 0.82 | DPP4 (0.47) | DPP4DPP7DPP8CYP2D6DPP9 | |
| SCHEMBL3940298 | 0.80 | DPP4 (0.56) | DPP4DPP7DPP8CYP2D6DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051323-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-8273752-B2 | Substituted imidazopyrimidines and triazolopyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113441-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | TYMP, DPYD, THPO | DPP4 436/4885DPP7 1082/4885DPP8 759/4885 |
| US-20130040946-A1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | THPO, TYMP, TPMT | DPP4 497/4885DPP7 1030/4885DPP8 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.